Probiotics: From Bench to Market

Annals of the New York Academy of Sciences

Volumn 1212, Issue SUPPL. 1, 2010, Pages

  Klein, Marguerite ^a   Sanders, Mary Ellen ^b   Duong, Tri ^c   Young, Howard A ^d  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b DAIRY AND FOOD CULTURE TECHNOLOGIES   (United States)

^c TEXAS A AND M UNIVERSITY   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Investigational new drug; Microbiota; Prebiotics; Probiotics

Indexed keywords

NEW DRUG; PROBIOTIC AGENT;

ARTICLE; CLINICAL TRIAL; DIET SUPPLEMENTATION; DRUG EFFECT; DRUG INFORMATION; DRUG MARKETING; DRUG RESEARCH; GASTROINTESTINAL TRACT; HUMAN; IMMUNE SYSTEM; NERVOUS SYSTEM; PUBLIC HEALTH SERVICE;

EID: 78649454373     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2010.05839.x     Document Type: Article

References (63)

1. Hill, C. 2010. Probiotics and pharmabiotics. Bioengineered Bugs 1: 79-84.
2. Shanahan, F., C. Stanton, P. Ross & C. Hill 2009. Pharmabiotics: Bioactives from mining host-microbe-dietary interactions. Functional Food Reviews 1: 20-25.
3. Kubota, A. et al 2009. Lactobacillus strains stabilize intestinal microbiota in Japanese cedar pollinosis patients. Microbiol. Immunol. 53: 198-205.
4. Engelbrektson, A. et al 2009. Probiotics to minimize the disruption of faecal microbiota in healthy subjects undergoing antibiotic therapy. J. Med. Microbiol. 58: 663-670.
5. Whorwell, P.J. et al 2006. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am. J. Gastroenterol. 101: 1581-1590.
6. Savino, F., E. Pelle, E. Palumeri, et al 2007. Lactobacillus reuteri (American Type Culture Collection Strain 55730) versus simethicone in the treatment of infantile colic: a prospective randomized study. Pediatrics 119: e124-130.
7. ISAPP. 2009. Probiotics: A Consumer Guide for Making Smart Choices.
8. WGO. 2008. WGO Practice Guidline-Probiotics and Prebiotics.
9. Floch, M.H. et al 2008. Recommendations for Probiotic Use-2008. J. Clin. Gastroenterol. 42(Suppl. 2): S104-108.
10. Ringel, Y. & I.M. Carroll 2009. Alterations in the intestinal microbiota and functional bowel symptoms. Gastrointest. Endosc. Clin. N. Am. 19: 141-150.
11. Barbara, G. et al 2005. Interactions between commensal bacteria and gut sensorimotor function in health and disease. Am. J. Gastroenterol. 100: 2560-2568.
12. Husebye, E., P.M. Hellstrom, F. Sundler, et al 2001. Influence of microbial species on small intestinal myoelectric activity and transit in germ-free rats. Am. J. Physiol. Gastrointest. Liver Physiol. 280: G368-G380.
13. Bercik, P. et al 2004. Visceral hyperalgesia and intestinal dysmotility in a mouse model of postinfective gut dysfunction. Gastroenterology 127: 179-187.
14. McFarland, L.V. & S. Dublin 2008. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J. Gastroenterol. 14: 2650-2661.
15. Moayyedi, P. et al 2010. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut 59: 325-332.
16. Bar, F. et al 2009. Cell-free supernatants of Escherichia coli Nissle 1917 modulate human colonic motility: evidence from an in vitro organ bath study. Neurogastroenterol. Motil. 21: 559-566, e516-557.
17. Marteau, P. et al 2002. Bifidobacterium animalis strain DN-173 010 shortens the colonic transit time in healthy women: a double-blind, randomized, controlled study. Aliment. Pharmacol. Ther. 16: 587-593.
18. Verdu, E.F. et al 2006. Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice. Gut 55: 182-190.
19. Ait-Belgnaoui, A. et al 2006. Lactobacillus farciminis treatment suppresses stress induced visceral hypersensitivity: a possible action through interaction with epithelial cell cytoskeleton contraction. Gut 55: 1090-1094.
20. Tracey, K.J. 2002. The inflammatory reflex. Nature 420: 853-859.
21. Mayer, E.A. & M.C. Bushnell 2009. Synthesis. In Functional Pain Syndromes: Presentation and Pathophysiology. E.A. Mayer & M.C. Bushnell, Eds. International Association for the Study of Pain.
22. Bailey, M.T. & C.L. Coe 1999. Maternal separation disrupts the integrity of the intestinal microflora in infant rhesus monkeys. Dev. Psychobiol. 35: 146-155.
23. O'Mahony, S.M. et al 2009. Early life stress alters behavior, immunity, and microbiota in rats: implications for irritable bowel syndrome and psychiatric illnesses. Biol. Psychiatry 65: 263-267.
24. Waldor, Matthew K. & V. Sperandio 2007. Adrenergic Regulation of Bacterial Virulence. J. Infect. Dis. 195: 1248-1249.
25. Cogan, T.A. et al 2007. Norepinephrine increases the pathogenic potential of Campylobacter jejuni. Gut 56: 1060-1065.
26. Gareau, M.G., J. Jury, G. MacQueen, et al 2007. Probiotic treatment of rat pups normalises corticosterone release and ameliorates colonic dysfunction induced by maternal separation. Gut 56: 1522-1528.
27. Sudo, N. et al 2004. Postnatal microbial colonization programs the hypothalamic-pituitary-adrenal system for stress response in mice. J. Physiol. 558: 263-275.
28. Rousseaux, C. et al 2007. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat. Med. 13: 35-37.
29. Mohamadzadeh, M., T. Duong, T. Hoover & T.R. Klaenhammer 2008. Targeting mucosal dendritic cells with microbial antigens from probiotic lactic acid bacteria. Expert Rev. Vaccines 7: 163-174.
30. Mohamadzadeh, M. & R. Luftig 2004. Dendritic cells: In the forefront of immunopathogenesis and vaccine development - A review. J. Immune Based Ther. Vaccines 2: 1.
31. Curiel, T.J. et al 2004. Peptides identified through phage display direct immunogenic antigen to dendritic cells. J. Immunol. 172: 7425-7431.
32. Mohamadzadeh, M. et al 2005. Lactobacilli activate human dendritic cells that skew T cells toward T helper 1 polarization. Proc. Natl. Acad. Sci. USA 102: 2880-2885.
33. Mohamadzadeh, M., T. Duong, S.J. Sandwick, et al 2009. Dendritic cell targeting of Bacillus anthracis protective antigen expressed by Lactobacillus acidophilus protects mice from lethal challenge. Proc. Natl. Acad. Sci. USA 106: 4331-4336.
34. Xu, J. et al 2003. A genomic view of the human-Bacteroides thetaiotaomicron symbiosis. Science 299: 2074-2076.
35. Sonnenburg, J.L. et al 2005. Glycan foraging in vivo by an intestine-adapted bacterial symbiont. Science 307: 1955-1959.
36. Sonnenburg, J.L., C.T. Chen & J.I. Gordon 2006. Genomic and metabolic studies of the impact of probiotics on a model gut symbiont and host. PLoS Biol. 4: e413.
37. Samuel, B.S. & J.I. Gordon 2006. A humanized gnotobiotic mouse model of host-archaeal-bacterial mutualism. Proc. Natl. Acad. Sci. USA 103: 10011-10016.
38. Sonnenburg, E.D. et al 2010. Specificity of polysaccharide use in intestinal bacteroides species determines diet-induced microbiota alterations. Cell 141: 1241-1252.
39. Corr, S.C. et al 2007. Bacteriocin production as a mechanism for the antiinfective activity of Lactobacillus salivarius UCC118. Proc. Natl. Acad. Sci. USA 104: 7617-7621.
40. Rea, M.C. et al 2010. Thuricin CD, a posttranslationally modified bacteriocin with a narrow spectrum of activity against Clostridium difficile. Proc. Natl. Acad. Sci. USA 107: 9352-9357.
41. Rea, M.C. et al 2010. Microbes and Health Sackler Colloquium: Effect of broad- and narrow-spectrum antimicrobials on Clostridium difficile and microbial diversity in a model of the distal colon. Proc. Natl. Acad. Sci. USA. [Epub ahead of print]
42. Depeint, F., G. Tzortzis, J. Vulevic, et al 2008. Prebiotic evaluation of a novel galactooligosaccharide mixture produced by the enzymatic activity of Bifidobacterium bifidum NCIMB 41171, in healthy humans: a randomized, double-blind, crossover, placebo-controlled intervention study. Am. J. Clin. Nutr. 87: 785-791.
43. Silk, D.B., A. Davis, J. Vulevic, et al 2009. Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome. Aliment. Pharmacol. Ther. 29: 508-518.
44. Vulevic, J., A. Drakoularakou, P. Yaqoob, et al 2008. Modulation of the fecal microflora profile and immune function by a novel trans-galactooligosaccharide mixture (B-GOS) in healthy elderly volunteers. Am. J. Clin. Nutr. 88: 1438-1446.
45. Drakoularakou, A., G. Tzortzis, R.A. Rastall & G.R. Gibson 2010. A double-blind, placebo-controlled, randomized human study assessing the capacity of a novel galacto-oligosaccharide mixture in reducing travellers' diarrhoea. Eur. J. Clin. Nutr. 64: 146-152.
46. O'Mahony, C. et al 2008. Commensal-Induced Regulatory T Cells Mediate Protection against Pathogen-Stimulated NF-κB Activation. PLoS Pathog 4: e1000112.
47. Sheil, B. et al 2006. Role of interleukin (IL-10) in probiotic-mediated immune modulation: an assessment in wild-type and IL-10 knock-out mice. Clin. Exp. Immunol. 144: 273-280.
48. O'Mahony, L. et al 2005. Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 128: 541-551.
49. Donato, K.A. et al 2008. Escherichia albertii and Hafnia alvei are candidate enteric pathogens with divergent effects on intercellular tight junctions. Microbial Pathogenesis 45: 377-385.
50. Turner, J.R. 2009. Intestinal mucosal barrier function in health and disease. Nat. Rev. Immunol. 9: 799-809.
51. Donato, K.A., M.G. Gareau, Y.J. Wang, et al 2010. Lactobacillus rhamnosus GG attenuates interferon-{gamma} and tumor necrosis factor-{alpha}-induced barrier dysfunction and pro-inflammatory signalling. Microbiology. [Epub ahead of print]
52. Agrawal, A. et al 2009. Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173-010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation. Aliment. Pharmacol. Ther. 29: 104-114.
53. Katakura, K. et al 2005. Toll-like receptor 9-induced type I IFN protects mice from experimental colitis. J. Clin. Invest. 115: 695-702.
54. Musch, E., T. Andus & M. Malek 2002. Induction and maintenance of clinical remission by interferon-beta in patients with steroid-refractory active ulcerative colitis-an open long-term pilot trial. Aliment. Pharmacol. Ther. 16: 1233-1239.
55. Pena-Rossi, C. et al 2008. Clinical trial: a multicentre, randomized, double-blind, placebo-controlled, dose-finding, phase II study of subcutaneous interferon-beta-la in moderately active ulcerative colitis. Aliment. Pharmacol. Ther. 28: 758-767.
56. Steidler, L. et al 2000. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 289: 1352-1355.
57. Alberti, K.G. et al 2009. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120: 1640-1645.
58. Putaala, H. et al 2008. Effect of four probiotic strains and Escherichia coli O157:H7 on tight junction integrity and cyclo-oxygenase expression. Res. Microbiol. 159: 692-698.
59. Kaloustian, S. et al 2009. Tumor necrosis factor-alpha participates in apoptosis in the limbic system after myocardial infarction. Apoptosis 14: 1308-1316.
60. Girard, S.-A. et al 2009. Lactobacillus helveticus and Bifidobacterium longum taken in combination reduce the apoptosis propensity in the limbic system after myocardial infarction in a rat model. Br. J. Nutr. 102: 1420-1425.
61. Public Health Service Act of 1944, 42, U.S.C. 262.
62. FDA. 2008. Guidance for Industry: Substantiation for Dietary Supplement Claims Made Under Section 403(r) (6) of the Federal Food, Drug, and Cosmetic Act.
63. FDA. 2009. Guidance for Industry: Evidence-Based Review System for the Scientific Evaluation of Health Claims.